XSPRAY Xspray Pharma AB (publ)

1.004USD10.18 SEK · STO-2.86%Mkt Cap: 49.95M USDP/E: —

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the…

Key Statistics

Company
Market Cap49.95M USD
Enterprise Value48.34M USD
Revenue (TTM)708.81K USD
Gross Profit243.17K USD
Net Income (TTM)-16.91M USD
Revenue/Share0.02 USD
Last Price1.004 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees24
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009973563
Valuation
P/E (Trailing)—
P/E (Forward)-6.40
PEG—
EV/EBITDA-3.67
EV/Revenue68.20
P/S70.47
P/B0.81
EPS (TTM)-0.32 USD
EPS (Forward)-0.16 USD
52W Range
0.89344% of range3.565
52W High3.565 USD
52W Low0.8934 USD
Profitability
Gross Margin100.00%
Oper. Margin-1882.85%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.35%
ROA-22.28%
ROIC-26.54%
ROCE-21.28%
Growth
Revenue Growth-41.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.05M USD
CapEx (TTM)2.88M USD
FCF Margin-1515.54%
FCF Yield-21.51%
Net Debt739.28K USD
Net Debt/EBITDA-0.06
Net Debt/FCF—
Balance Sheet
Debt/Equity0.25
Current Ratio1.14
Quick Ratio0.90
Book Value/Sh1.24 USD
Cash/Share0.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.668 USD
Upside (mean)+265.4%
Target Range3.668 USD – 3.668 USD
# Analysts1
Ownership
Shares Out.49.76M
Float33.91M
Insiders22.74%
Institutions43.94%
Technical
SMA 501.044 (-3.9%)
SMA 2001.781 (-43.6%)
Beta0.00
S&P 52W Chg8.68%
Avg Vol (30d)75.78K
Avg Vol (10d)150.02K
Technical Indicators
RSI (14)42.7
MACD-0.0367
MACD Signal0.1705
MACD Hist.-0.2072
BB Upper1.298 USD
BB Middle1.118 USD
BB Lower0.9386 USD
BB Width32.10%
ATR (14)0.1028 USD
Vol Ratio (20d)1.17x

About Xspray Pharma (STO: XSPRAY)

›

Xspray Pharma (STO: XSPRAY) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.

The shares were at 10.18 SEK on 20 November 2026, down 61.1% over 52 weeks. Its 52-week range is 9.060 SEK to 36.15 SEK: the price is 71.8% below the high and 12.4% above the low.

Its market capitalisation is 506.55M SEK.

Xspray Pharma reports return on equity of -28.4% and revenue down 41.1% year over year.

Its debt exceeds its cash by 7.50M SEK, a debt-to-equity ratio of 0.25. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 37.20 SEK is 265.4% above the current price.